Description
Using our intelligently designed and intuitive dataset, you can quickly understand how Bristol-Myers Squibb Company (BMY) is lobbying the U.S. government, how much they’re spending on it, and most importantly – the bills and specific issues on which they lobby.
Gain an informational edge with our Lobbying Data Intelligence. Perform analysis by company, lobbyist, lobbying firm, government agency, or issue.
For lobbying firms: understand your competitors. Understand who is registering with who. Gain insight on quarterly reports and specific issues other firms are lobbying on.
Our lobbying data is collected and aggregated from the U.S. Senate Office of Public Records from 1999-present and is updated on a regular basis. We utilize advanced data science techniques to ensure accurate data points are collected and ingested, match similar entities across time, and tickerize publicly traded companies that lobby.
Our comprehensive and advanced lobbying database is completed with all the information you need, with more than 1.6 million lobbying contracts ready-for-analysis. We include detailed information on all aspects of federal lobbying, including the following fascinating attributes, among much more:
1. Clients: The publicly traded company, privately owned company, interest group, NGO, or state or local government that employs or retains a lobbyist or lobbying firm.
2. Registrants (Lobbying Firms): Either the name of the lobbying firm hired by the client, or the name of the client if the client employs in-house lobbyists.
3. Lobbyists: The names and past government work experience of the individual lobbyists working on a lobbying contract. 3. General Issues: The general issues for which clients lobby on (ex: ENV – Environment, TOB – Tobacco, FAM – Family Issues/Abortion).
4. Specific Issues: A long text description of the exact bills and specific issues for which clients lobby on.
5. Bills Lobbied On: The exact congressional bills and public/private laws lobbied on, parsed from lobbying report specific issues (ex: H.R. 2347, S. 1117, Tax Cuts and Jobs Act).
6. Agencies Lobbied: The names of one or more of 250+ government agencies lobbied on in the contract (ex: White House, FDA, DOD).
7. Foreign Entities: The names and origin countries of entities affiliated with the client (ex: BNP Paribas: France).
Gain access to our highly unique and actionable U.S. lobbying database. Further information on LobbyingData.com and our alternative datasets and database can be found on our website, or by contacting [email protected].
Frequently Asked Questions
What is Bristol-Myers Squibb Company (BMY) lobbying for?
Summary of the lobbying data:
Bristol-Myers Squibb Company hired 10 lobbying firms to lobby on general issues such as taxation/internal revenue code, health issues, Medicare/Medicaid, copyright/patent/trademark, trade (domestic/foreign) and budget/appropriations. They also lobbied on specific issues such as pricing, drug pricing, 340B drug pricing program, tax cuts and jobs act, prescription drug access and affordability, WTO TRIPS waiver process, pharmaceutical IP and supply chain, prescription drug prices in Medicare and Medicaid programs, Medicare parts B&D, inflation reduction act, biopharmaceutical innovation and patent policy issues, trademark legislative proposals, Bayh-Dole march-in rights policy issues, FDA, transparency, remove barriers to healthcare access and identify social determinants of health, CARES Act implementation, and international pharmaceutical supply chain. The company lobbied both the Senate and the House of Representatives.
Inference about why the company is lobbying on the issues:
One could infer that Bristol-Myers Squibb Company is lobbying on these issues to influence lawmakers on policies related to healthcare, drug pricing, patent/trademark laws, trade regulations, and budget appropriations. They may be seeking favorable changes to various laws and regulations that impact their business, and attempting to protect their intellectual property and patents through legislative means. Additionally, they may be seeking to gain a competitive advantage in the market through lobbying efforts.
